The global Brahmi market is projected to grow by USD 61,934.9 million from 2025-2029 at a CAGR of 6.8%, driven by research validating Bacopa monnieri for memory enhancement and its rise as a natural nootropic for cognitive decline, stress, and anxiety. In November 2024, Sabinsa Corp. secured a research grant for clinical trials on a high-potency Brahmi formulation targeting age-related cognitive decline. Advancements in extraction methods have improved phytochemical purity by 15%, aiding regulatory clearance and consumer trust in US nutraceutical products.

This peer-reviewed study demonstrates that Brahmi Plant Preparation (BPP) from Bacopa monnieri enhances dendritic cell activation, induces Th1-biased immune responses, and modulates epigenetics against non-small cell lung cancer (NSCLC) in vitro. It shows potential to improve therapeutic efficacy, reduce side effects, and boost quality of life when included in NSCLC regimens. Further in vivo and translational research is recommended to confirm its role as a low-toxicity epi-modulator.

This double-blind, randomized trial protocol (CTRI/2025/02/081239) investigates combining Brahmi tablets with Cognitive Behavioral Therapy (CBT) versus CBT alone for managing moderate to severe premenstrual syndrome (PMS) in women aged 18-24. Primary outcomes focus on PMS severity reduction and quality of life improvement, with secondary measures of functional disability. Sponsored by the Central Council for Research in Ayurveda Sciences, it aims to provide preliminary evidence for integrative PMS treatment.